Surgical sealant maker Cohera Medical said it’s raised $17 million so far in its Series D funding round with a $7.3 million contribution from 23 unnamed private investors.
Cohera, which makes surgical adhesives and sealants, said it plans to use the cash to expand adoption of its TissuGlu product in Germany and "additional European markets" and to advance its 1st U.S. clinical trial, according to a press release.
Last year the FDA OK’d the 1st phase of a modular application for pre-market approval for the TissueGlu sealant, which won CE Mark approval in September 2011. The Pittsburgh-based company raised about $9.7 million in a prior tranche of the round back in June 2012.
Cohera said it also plans to begin trials of its Sylys sealant in Europe.
"This funding milestone is instrumental, as we begin the No Drain clinical trial for TissuGlu in the United States and start human clinical trials of our Sylys product," president & CEO Patrick Daly said in prepared remarks. "Our products have the potential to revolutionize how patients recover from many types of large flap procedures. From abdominoplasties and mastectomies to lymph node dissection in cancer patients and bowel procedures, our adhesive and sealant technologies will transform patient experiences."